secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001628280-24-005061
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis completes stock option exchange; 98% of eligible options surrendered for 2.13M new RSUs
--------------------------------------------------------------------------------

- Options to purchase 5.06M shares surrendered (~98% of eligible); 2.13M new RSUs issued.
- CEO Todd Franklin Watanabe surrendered 584,500 options, received 264,882 new RSUs.
- Executive officers participated; non-employee directors excluded. Exchange ratios 2:1, 2.5:1, 3:1 based on exercise price.
- New RSUs vest quarterly over 1-3 years starting Feb 1, 2024, subject to continued service.
- Surrendered options had exercise prices significantly above recent trading price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000162828024005061/0001628280-24-005061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000162828024005061/arqt-20240212.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-005061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer